BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 31030566)

  • 41. Pulsatile gonadotropin releasing hormone therapy for spermatogenesis in congenital hypogonadotropic hypogonadism patients who had poor response to combined gonadotropin therapy.
    Huang Z; Wang X; Yu B; Ma W; Zhang P; Wu X; Nie M; Mao J
    Arch Endocrinol Metab; 2024 May; 68():e230101. PubMed ID: 38739523
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Seminal anti-Müllerian hormone level is a marker of spermatogenic response during long-term gonadotropin therapy in male hypogonadotropic hypogonadism.
    Sinisi AA; Esposito D; Maione L; Quinto MC; Visconti D; De Bellis A; Bellastella A; Conzo G; Bellastella G
    Hum Reprod; 2008 May; 23(5):1029-34. PubMed ID: 18343809
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China.
    Hsing AW; Gao YT; Wu G; Wang X; Deng J; Chen YL; Sesterhenn IA; Mostofi FK; Benichou J; Chang C
    Cancer Res; 2000 Sep; 60(18):5111-6. PubMed ID: 11016637
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Endocrine profiles and gonadotropin response to Gn-RH of men with testicular cancer].
    Watanabe M; Fuji K; Suzuki K; Kitamura T; Okumura D; Kasahara T; Igarashi T; Masuyama T; Hiramori T; Higaki M; Yoshida H
    Nihon Hinyokika Gakkai Zasshi; 2003 Jul; 94(5):543-50. PubMed ID: 12910930
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cytogenetic and molecular analysis of infertile Chinese men: karyotypic abnormalities, Y-chromosome microdeletions, and CAG and GGN repeat polymorphisms in the androgen receptor gene.
    Han TT; Ran J; Ding XP; Li LJ; Zhang LY; Zhang YP; Nie SS; Chen L
    Genet Mol Res; 2013 Jul; 12(3):2215-26. PubMed ID: 23884765
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Larger trinucleotide repeat size in the androgen receptor gene of infertile men with extremely severe oligozoospermia.
    Patrizio P; Leonard DG; Chen KL; Hernandez-Ayup S; Trounson AO
    J Androl; 2001; 22(3):444-8. PubMed ID: 11330644
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Response to Gonadotropin-Releasing Hormone and hCG in Men with Prior Chronic Androgen Steroid Abuse and Clinical Hypogonadism.
    Flanagan JN; Lehtihet M
    Horm Metab Res; 2015 Aug; 47(9):668-73. PubMed ID: 25642745
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hormonal regulation of male reproduction (with reference to infertility in man).
    Courot M
    Andrologia; 1976; 8(3):187-93. PubMed ID: 999040
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Constitutional delayed puberty in males and hypogonadotropic hypogonadism: a reliable and cost-effective approach to differential diagnosis.
    Martin MM; Martin AL
    J Pediatr Endocrinol Metab; 2005 Sep; 18(9):909-16. PubMed ID: 16279369
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Induction of spermatogenesis by recombinant follicle-stimulating hormone (puregon) in hypogonadotropic azoospermic men who failed to respond to human chorionic gonadotropin alone.
    Bouloux PM; Nieschlag E; Burger HG; Skakkebaek NE; Wu FC; Handelsman DJ; Baker GH; Ochsenkuehn R; Syska A; McLachlan RI; Giwercman A; Conway AJ; Turner L; van Kuijk JH; Voortman G
    J Androl; 2003; 24(4):604-11. PubMed ID: 12826700
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gonadotropins for pubertal induction in males with hypogonadotropic hypogonadism: systematic review and meta-analysis.
    Alexander EC; Faruqi D; Farquhar R; Unadkat A; Ng Yin K; Hoskyns R; Varughese R; Howard SR
    Eur J Endocrinol; 2024 Jan; 190(1):S1-S11. PubMed ID: 38128110
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Absence of effect of recombinant growth hormone to classic gonadotropin treatment on spermatogenesis of patients with severe hypogonadotropic hypogonadism.
    Giagulli VA
    Arch Androl; 1999; 43(1):47-53. PubMed ID: 10445104
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Alleles with short CAG and GGN repeats in the androgen receptor gene are associated with benign endometrial cancer.
    Rodríguez G; Bilbao C; Ramírez R; Falcón O; León L; Chirino R; Falcón O; Díaz BP; Rivero JF; Perucho M; Díaz-Chico BN; Díaz-Chico JC
    Int J Cancer; 2006 Mar; 118(6):1420-5. PubMed ID: 16187285
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Length of androgen receptor-CAG repeats in fertile and infertile Egyptian men.
    Badran WA; Fahmy I; Abdel-Megid WM; Elder K; Mansour R; Kent-First M
    J Androl; 2009; 30(4):416-25. PubMed ID: 19168451
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Androgen receptor gene polymorphisms and the fat-bone axis in young men and women.
    Ponce-González JG; Guadalupe-Grau A; Rodríguez-González FG; Dorado C; Olmedillas H; Fuentes T; Rodríguez-García L; Díaz-Chico BN; Calbet JA
    J Androl; 2012; 33(4):644-50. PubMed ID: 21940984
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Associations between androgen receptor CAG & GGN repeat polymorphism & recurrent spontaneous abortions in Chinese women.
    Chuan Z; Jie D; Hao X; Junhua B; Mengjing G; Liguo P; Yousheng Y; Hong L; Zhenghao H
    Indian J Med Res; 2014 May; 139(5):730-6. PubMed ID: 25027083
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Induction of spermatogenesis in isolated hypogonadotropic hypogonadism with exogenous human chorionic gonadotropin.
    Luboshitzky R; Dickstein G; Barzilai D
    J Endocrinol Invest; 1981; 4(2):217-9. PubMed ID: 6792265
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pulsatile gonadotropin-releasing hormone therapy is associated with earlier spermatogenesis compared to combined gonadotropin therapy in patients with congenital hypogonadotropic hypogonadism.
    Mao JF; Liu ZX; Nie M; Wang X; Xu HL; Huang BK; Zheng JJ; Min L; Kaiser UB; Wu XY
    Asian J Androl; 2017; 19(6):680-685. PubMed ID: 28051040
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes.
    Stanworth RD; Kapoor D; Channer KS; Jones TH
    Eur J Endocrinol; 2008 Dec; 159(6):739-46. PubMed ID: 18805913
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Human chorionic gonadotropin treatment: a viable option for management of secondary hypogonadism and male infertility.
    Fink J; Schoenfeld BJ; Hackney AC; Maekawa T; Horie S
    Expert Rev Endocrinol Metab; 2021 Jan; 16(1):1-8. PubMed ID: 33345656
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.